Study Reports Linezolid-Resistant Staplylococcus aureus (LRSA) Outbreak

June 8, 2010

A study presented in the June 9, pharm 2010 issue of JAMA reports an outbreak of linezolid and methicillin-resistant Staplylococcus aureaus (LRSA) in the intensive care department of a teaching hospital in Madrid, Spain.

Linezolid is a relatively new antibiotic and has been considered as one of the few methods for treating MRSA infections.

The study found that between the months of April 13 and June 26, 2008, 12 patients with LRSA were identified at the hospital.  LRSA caused ventilator-associated pneumonia (VAP) in 6 patients, bacteremia in 3, and 1 death. The patients were in “a subgroup of high-risk critically ill patients with prolonged ICU stays and risk factors for antibiotic resistance.”

The authors conclude the outbreak was due to nosocomial transmission and the extensive use of linezolid.  The outbreak was controlled by reducing linezolid use and improving infection control measures.

Reference:  Garcia, Miguel Sanchez, et al.  Clinical Outbreak of Linezolid-Resistant Staplylococcus aureus in an Intensive Care Unit.  JAMA, 303(22):2260-2264 (2010).

Leave a Comment

Previous post:

Next post: